Publicaciones en colaboración con investigadores/as de Universitat de Barcelona (13)

2024

  1. Ten-year prognostic impact of target versus non-target vessel failure after STEMI. Insight from the EXAMINATION-EXTEND trial

    Revista Espanola de Cardiologia, Vol. 77, Núm. 3, pp. 215-225

2023

  1. Relationship between stent length and very long-term target lesion failure following percutaneous coronary intervention for ST-elevation myocardial infarction in the drug-eluting stents era: insights from the EXAMINATION-EXTEND study

    American Heart Journal, Vol. 264, pp. 72-82

2021

  1. 10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction

    Journal of the American College of Cardiology, Vol. 77, Núm. 9, pp. 1165-1178

2020

  1. Angiographic and clinical outcomes of STEMI patients treated with bioresorbable or metallic everolimus-eluting stents: A pooled analysis of individual patient data

    EuroIntervention, Vol. 14, Núm. 16, pp. 1451-1457

  2. Bioresorbable scaffolds versus everolimus-eluting metallic stents: Five-year clinical outcomes of the randomised ABSORB II trial

    EuroIntervention, Vol. 16, Núm. 11, pp. E938-E941

  3. Endothelial shear stress and vascular remodeling in bioresorbable scaffold and metallic stent

    Atherosclerosis, Vol. 312, pp. 79-89

  4. Position statement of the Interamerican Society of Cardiology (IASC) on the current guidelines for the prevention, diagnosis and treatment of arterial hypertension 2017–2020

    International Journal of Cardiology: Hypertension, Vol. 6

  5. Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) trial: Rationale and study design

    American Heart Journal, Vol. 222, pp. 174-182

2018

  1. Four-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II Trial)

    EuroIntervention, Vol. 13, Núm. 13, pp. 1561-1564

  2. Three-year follow-up of the randomised comparison between an everolimus-eluting bioresorbable scaffold and a durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction (TROFI II trial)

    EuroIntervention, Vol. 14, Núm. 11, pp. E1224-E1226

2016

  1. Arterial healing following primary PCI using the Absorb everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) versus the durable polymer everolimus-eluting metallic stent (XIENCE) in patients with acute ST-elevation myocardial infarction: Rationale and design of the randomised TROFI II study

    EuroIntervention, Vol. 12, Núm. 4, pp. 482-489

2015

  1. Acceso radial frente a femoral en angioplastia por infarto agudo de miocardio con elevación del segmento ST con stent farmacoactivo de segunda generación

    Revista Espanola de Cardiologia, Vol. 68, Núm. 1, pp. 47-53

2013

  1. Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction: Insights from the EXAMINATION trial

    American Heart Journal, Vol. 166, Núm. 1